Moderna, Inc.
MRNAAPI behind this page
MRNA Q3 2025 request
Playground key active
/api/financials?ticker=MRNA&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 1,016 | 1,862 | -45.4% |
Show Product Lines breakouts |
|||
| Collaboration Arrangement, Including Arrangements With Affiliate [Member] | 7 | 28 | -75.0% |
| COVID(1) | 971 | 1,810 | -46.4% |
| Grant | 14 | 7 | +100.0% |
| Licensing and royalty revenue | 2 | 7 | -71.4% |
| Net product sales | 973 | 1,820 | -46.5% |
| Net product sales · Europe | 16 | 281 | -94.3% |
| Net product sales · Rest of world | 175 | 324 | -46.0% |
| Net product sales · US | 782 | 1,215 | -35.6% |
| Other revenue | 20 | — | — |
| Product And Service Other | 43 | 42 | +2.4% |
| RSV | 2 | 10 | -80.0% |
| Cost of Revenue | 207 | 514 | -59.7% |
| Research & Development | 801 | 1,137 | -29.6% |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences (Blackstone) · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 25 | 30 | -16.7% |
| Merck · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 101 | 109 | -7.3% |
| General & Administrative | 268 | 281 | -4.6% |
| Total Costs & Expenses | 1,276 | 1,932 | -34.0% |
| Operating Income | -260 | -70 | -271.4% |
| Interest Income | 73 | 103 | -29.1% |
| Income Before Taxes | -187 | 21 | -990.5% |
| Income Tax Expense (Benefit) | 13 | 8 | +62.5% |
| Net Income | -200 | 13 | -1638.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | -200 | 13 | -1638.5% |
| EPS (Basic) | -0.51 | 0.03 | -1800.0% |
| EPS (Diluted) | -0.51 | 0.03 | -1800.0% |
| Wtd Avg Shares (Basic) | 390 | 385 | +1.3% |
| Wtd Avg Shares (Diluted) | 390 | 399 | -2.3% |
| Comprehensive Income | -196 | 95 | -306.3% |
| Other Comprehensive Income | 4 | 82 | -95.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 2 | — | — |
| Accumulated Net Unrealized Investment Gain Loss | 5 | — | — |
| Accumulated Other Comprehensive Income | 4 | 82 | -95.1% |
| Accumulated Translation Adjustment | -3 | — | — |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,132 | 1,644 | -31.1% |
| Available For Sale Securities Debt Securities Current | 3,372 | 5,223 | -35.4% |
| Accounts Receivable | 1,046 | 1,564 | -33.1% |
| Inventory | 332 | — | — |
| Prepaid Expenses & Other Current Assets | 716 | 823 | -13.0% |
| Total Current Assets | 6,598 | 9,666 | -31.7% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 2,143 | 2,335 | -8.2% |
| Operating Lease Right-of-Use Assets | 738 | 784 | -5.9% |
| Other Non-Current Assets | 530 | 556 | -4.7% |
| Total Assets | 12,135 | 15,803 | -23.2% |
| Goodwill | 52 | 52 | 0.0% |
| Intangible Assets | 47 | 41 | +14.6% |
| Deferred Tax Assets | 81 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2,126 | — | — |
| Current Liabilities | |||
| Accounts Payable | 267 | 373 | -28.4% |
| Accrued Liabilities | 1,178 | 1,376 | -14.4% |
| Deferred Revenue (Current) | 163 | 379 | -57.0% |
| Other Liabilities Current | 73 | 69 | +5.8% |
| Total Current Liabilities | 1,681 | 2,201 | -23.6% |
| Non-Current Liabilities | |||
| Contract With Customer Liability Noncurrent | 157 | 95 | +65.3% |
| Operating Lease Liabilities | 660 | 679 | -2.8% |
| Finance Lease Liability Noncurrent | 26 | 625 | -95.8% |
| Other Non-Current Liabilities | 281 | 276 | +1.8% |
| Total Liabilities | 2,805 | 3,876 | -27.6% |
| Deferred Tax Liabilities | 239 | 241 | -0.8% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 1,254 | 751 | +67.0% |
| Accumulated Other Comprehensive Income | 27 | 11 | +145.5% |
| Retained Earnings | 8,049 | 11,165 | -27.9% |
| Total Stockholders' Equity | 9,330 | 11,927 | -21.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -9 | -9 | 0.0% |
| Accumulated Net Unrealized Investment Gain Loss | 35 | 12 | +191.7% |
| Accumulated Other Comprehensive Income | 27 | 11 | +145.5% |
| Accumulated Translation Adjustment | 1 | 8 | -87.5% |
| Additional Paid In Capital | 1,254 | 751 | +67.0% |
| Retained Earnings | 8,049 | 11,165 | -27.9% |
| Total Liabilities & Equity | 12,135 | 15,803 | -23.2% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 370 | 325 | +13.8% |
| Other Depreciation And Amortization | 148 | 129 | +14.7% |
| Investment Income Net Amortization Of Discount And Premium | -54 | -76 | +28.9% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 5 | 43 | -88.4% |
| Other Non-Cash Items | 50 | 6 | +733.3% |
| Change in Accounts Receivable | -703 | -672 | -4.6% |
| Change in Prepaid & Other Assets | -84 | -147 | +42.9% |
| Change in Inventory | -213 | -208 | -2.4% |
| Increase Decrease In Right Of Use Asset Operating Leases | 28 | -63 | +144.4% |
| Change in Accounts Payable | -114 | -103 | -10.7% |
| Increase Decrease In Accrued Liabilities | -196 | -415 | +52.8% |
| Change in Deferred Revenue | 108 | -177 | +161.0% |
| Increase Decrease In Operating Lease Liability | -15 | 33 | -145.5% |
| Increase Decrease In Other Operating Liabilities | -137 | -63 | -117.5% |
| Net Cash from Operations | -2,803 | -3,829 | +26.8% |
| Depreciation & Amortization | 145 | 126 | +15.1% |
| Investing Activities | |||
| Purchases of Investments | -4,221 | -4,641 | +9.0% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 4,634 | 4,648 | -0.3% |
| Proceeds From Sale Of Available For Sale Securities Debt | 1,744 | 3,010 | -42.1% |
| Capital Expenditures | -153 | -529 | +71.1% |
| Payments To Acquire Intangible Assets | -10 | — | — |
| Net Cash from Investing | 1,994 | 2,488 | -19.9% |
| Financing Activities | |||
| Proceeds From Stock Plans | 19 | 55 | -65.5% |
| Tax Withholding for Share Compensation | -1 | — | — |
| Finance Lease Principal Payments Net Of Adjustments | -6 | 4 | -250.0% |
| Net Cash from Financing | 12 | 59 | -79.7% |
| Supplemental | |||
| Unpaid Capital Expenditures | 42 | 78 | -46.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2 | 1 | +100.0% |
| Net Change in Cash | -795 | -1,281 | +37.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,134 | 1,647 | -31.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.